|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Health Discovery Corporation (DWCM.OB) Announces Publication of Peer Reviewed Scientific Paper Demonstrating the Clinical Validity of the Four-Gene Prostate Cancer Test Licensed to Abbott GmbH, Quest Diagnostics Inc. (DGX) and Clarient, Inc.
7/14/2009
SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY), a molecular diagnostics company specializing in personalized medicine, announced today that its scientific paper entitled “A Four-Gene Expression Signature for Prostate Cancer Cells Consisting of UAP1, PDLIM5, IMPDH2, and HSPD1” has successfully completed the peer review process and has been approved for publication in the August issue of UroToday International Journal. This publication demonstrates the clinical validity of the four-gene prostate cancer test for identifying clinically significant prostate cancer licensed for commercialization by HDC to Abbott (NYSE: ABT), Quest Diagnostics (NYSE: DGX), and Clarient (NasdaqCM: CLRT).
|
|
|
|
|
|
|
|
|
|
|
|